The United States market has shown a steady performance, remaining flat over the last week but up 15% over the past year, with earnings forecasted to grow by 18% annually. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable conditions.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Fabrinet | 21.13% | 21.40% | ★★★★★★ |
| TG Therapeutics | 21.58% | 21.53% | ★★★★★★ |
| Ciena | 22.09% | 35.00% | ★★★★★★ |
| Lumentum Holdings | 33.89% | 97.87% | ★★★★★★ |
| Insmed | 32.16% | 67.21% | ★★★★★★ |
| Madrigal Pharmaceuticals | 27.87% | 64.15% | ★★★★★★ |
| Shopify | 20.17% | 21.03% | ★★★★★★ |
| Travere Therapeutics | 23.99% | 53.11% | ★★★★★★ |
| Precigen | 37.10% | 54.04% | ★★★★★★ |
| Snowflake | 21.06% | 57.42% | ★★★★★★ |
Click here to see the full list of 26 stocks from our US High Growth Tech and AI Stocks screener.
Here's a peek at a few of the choices from the screener.
TG Therapeutics (TGTX)
Simply Wall St Growth Rating: ★★★★★★
Overview: TG Therapeutics, Inc. is a commercial stage biopharmaceutical company dedicated to acquiring, developing, and commercializing innovative treatments for B-cell mediated diseases globally, with a market cap of $7.85 billion.
Operations: TG Therapeutics focuses on developing and commercializing treatments for B-cell mediated diseases, with its revenue primarily generated from the biotechnology startups segment amounting to $799.54 million.
TG Therapeutics is making notable strides in the biotech sector, particularly with its innovative approaches in multiple sclerosis treatments. The company recently showcased promising Phase 1 results for its CAR T-Cell therapy at the MSToronto2026, signaling potential breakthroughs in progressive multiple sclerosis treatment. Financially, TG Therapeutics has demonstrated robust growth with a significant revenue increase to $445.25 million in the first half of 2026 from $262 million the previous year, alongside an impressive annual revenue growth forecast of 21.6%. This performance is complemented by a raised full-year revenue guidance to approximately $950 million, reflecting strong market confidence and strategic execution. These developments not only underscore TG Therapeutics' commitment to advancing medical science but also highlight its potential as a dynamic player within high-growth sectors of biotechnology.
- Take a closer look at TG Therapeutics' potential here in our health report.
Review our historical performance report to gain insights into TG Therapeutics''s past performance.
Praxis Precision Medicines (PRAX)
Simply Wall St Growth Rating: ★★★★★★
Overview: Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance in the United States, with a market cap of $7.26 billion.
Operations: Praxis Precision Medicines develops therapies targeting central nervous system disorders in the U.S. and operates as a clinical-stage biopharmaceutical entity.
Praxis Precision Medicines, despite its current unprofitability, is poised for significant growth with a forecasted revenue increase of 64.7% per year, outpacing the US market's average of 13.8%. The company's commitment to innovation was highlighted at the recent Global Healthcare Conference, underscoring its potential in biotech. Moreover, Praxis is expected to turn profitable within three years with an anticipated earnings growth of 71.7% per year, reflecting strong future prospects despite a substantial net loss of $176.28 million in the first half of 2026. This trajectory suggests Praxis could be a key contributor to advancements in precision medicine technology.
- Get an in-depth perspective on Praxis Precision Medicines' performance by reading our health report here.
Understand Praxis Precision Medicines' track record by examining our Past report.
Ciena (CIEN)
Simply Wall St Growth Rating: ★★★★★★
Overview: Ciena Corporation is a network technology company that offers hardware, software, and services to network operators across multiple regions worldwide, with a market capitalization of approximately $63.78 billion.
Operations: Ciena generates revenue primarily through its Networking Platforms segment, which accounts for $4.83 billion, followed by Global Services at $714.38 million. The Platform Software and Services segment contributes $379.28 million, while Blue Planet Automation Software and Services adds $100.75 million to the overall revenue mix.
Ciena has demonstrated robust performance with a significant uptick in earnings, growing by 365.8% over the past year, surpassing the Communications industry average of 14.8%. This growth trajectory is supported by strategic initiatives like the deployment of next-generation optical solutions for e& UAE, enhancing digital infrastructure capabilities across regions. Additionally, Ciena's recent trial with Quantum Corridor Inc. showcases its forward-looking approach by integrating quantum-safe encryption technologies, positioning it well amidst escalating cybersecurity demands and future tech trends. These efforts are complemented by a healthy financial outlook with revenue expected to grow at 22.1% annually, outpacing the US market prediction of 13.8%, and earnings projected to rise by 35% per year.
- Unlock comprehensive insights into our analysis of Ciena stock in this health report.
Evaluate Ciena's historical performance by accessing our past performance report.
Next Steps
- Click this link to deep-dive into the 26 companies within our US High Growth Tech and AI Stocks screener.
- Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
- Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.
Ready To Venture Into Other Investment Styles?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com